Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A randomised controlled trial (RCT) and economic evaluation of direct versus indirect and individual versus group modes of speech and language therapy for children with primary language impairment
Source of recordUK Trials
ISRCTNISRCTN94684735
Date ISRCTN assigned25/04/2003
Local reference number(s)HTA 99/36/04
Public titleA randomised controlled trial (RCT) and economic evaluation of direct versus indirect and individual versus group modes of speech and language therapy for children with primary language impairment
Scientific title
AcronymN/A
Disease/condition/study domainNervous system diseases: Other nervous system disease
Study hypothesis1. To compare direct individual therapy (speech and language therapists working with children), indirect individual therapy (speech and language assistants working directly with children), direct group therapy (SLTs working with small groups of children) & indirect group therapy (SLAs working with small groups of children) with regard to the outcomes for school-age children with persistent primary receptive and/or expressive language impairment relative to a comparison group receiving current models and levels of SLT service.
2. To investigate the long-term benefits for such children from their therapy at 12 months follow-up.
3. To compare the four approaches in terms of cost.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteriaChildren with language impairment
Participants - exclusion criteriaNot provided at time of registration.
Patient information material
Anticipated start date01/04/2002
Anticipated end date30/06/2005
Status of trialCompleted
Target number of participantsNot provided at time of registration.
Interventions1. Direct individual therapy (speech and language therapists [SLTs] working with children)
2. Indirect individual therapy (speech and language assistants [SLAs] working directly with children)
3. Direct group therapy (SLTs working with small groups of children)
4. Indirect group therapy (SLAs working with small groups of children)
5. Current models of standard care
Primary outcome measure(s)Not provided at time of registration.
Secondary outcome measure(s)Not provided at time of registration.
PublicationsResults: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17610807
Sources of fundingNIHR Health Technology Assessment Programme - HTA (UK)
Sponsor nameDepartment of Health (UK)
Sponsor detailsQuarry House
Quarry Hill
Leeds
United Kingdom
LS2 7UE
Sponsor emailSheila.Greener@doh.gsi.gov.uk
Sponsor websitehttp://www.dh.gov.uk/en/index.htm
Contact nameMr James Boyle
Contact detailsDepartment of Psychology
Graham Hills Building
40 George Street
Glasgow
United Kingdom
G1 1QE
Contact telephone+44 (0)141-548 2584
Contact fax+44 (0)141 548 4001
Contact emailj.boyle@strath.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN94684735
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central